Rita Assi
This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.
Inclusion Criteria: 1. ≥ 18 years old at the time of informed consent 2. Ability to provide written informed consent and HIPAA authorization 3. Willingness to comply with all study procedures and be available for the duration of the trial 4. Have a performance status of 0 to 2 on the ECOG Performance Scale. 5. Life expectancy ≥12 weeks as per investigator discretion 6. Patients with histologically proven, relapsed or refractory HL or B-NHL as follows: 1. HL after failure of at least 1 prior line of systemic therapy 2. Primary mediastinal large B-cell lymphoma (PMBCL) that is refractory…
150 mg/m2 ATRA orally for 3 days surrounding each of the first four cycles (day -1, day 0, day +1)
200mg Q3W pembrolizumab
Arctuva estimate
Verify or correct the compensation shown for this listing.